Renown Institute for Heart & Vascular Health Conducts First Farapulse™ Procedure In Nevada to Treat Atrial Fibrillation
May 13, 2024
PICTURED ABOVE: Members of the Renown Institute for Heart & Vascular Health celebrate the first FARAPULSE™ procedure in Nevada on March 18, 2024.
Physicians, nurses and clinicians at the Renown Institute for Heart & Vascular Health have achieved a groundbreaking milestone as they successfully completed the first cardiac ablation procedure done in Nevada, utilizing the FARAPULSE™ Pulsed Field Ablation System this past March.
"Atrial fibrillation, commonly known as Afib or AF, is an irregular heartbeat caused by an abnormal heart rhythm that makes the upper heart chambers (the atria) quiver or fibrillate. It’s the most common heart rhythm irregularity—or cardiac arrhythmia—and it’s estimated that by 2030, 12.1 million people in the U.S. may have Afib,” said Rahul Mediwala, MD, MBA, CEO of Renown Medical Group. “While Afib itself generally is not life-threatening, the complications from Afib can be very serious, as it can increase the risk for heart problems such as heart failure and stroke. We are pleased to introduce additional therapies that allow physicians to serve more patients, reduce complications and benefit overall public health.”
"Our team takes immense pride in pioneering Nevada's first cardiac ablation procedure with the FARAPULSE™ Pulsed Field Ablation System, an FDA-approved innovation for atrial fibrillation treatment,” said Shining Sun, MD, a board-certified cardiologist trained in the procedure, at the Renown Institute for Heart & Vascular Health.
“This milestone represents a significant leap forward in cardiac care and underscores our commitment to advancing innovative treatments for atrial fibrillation, said Matthew Cain, MD, a board-certified cardiac electrophysiologist trained in the procedure. “We anticipate a significant reduction in anesthesia duration and wait times for patients undergoing this FDA-approved procedure due to its efficiency.”
What is Atrial Fibrillation?
Atrial fibrillation (AF) occurs when the top two chambers of the heart, the atria, beat too fast and with an irregular rhythm (fibrillation). AF, the most common type of arrhythmia, can decrease the heart’s pumping efficiency, which can cause blood cells to pool and stick together, forming clots in the heart, and lead to stroke. People with AF have a higher risk of stroke, heart failure and other heart-related complications than those with normal heart rhythms. AF affects nearly 2% of the general population worldwide, and approximately seven million Americans live with this arrhythmia. An estimated 38 million people globally have AF.
About the FARAPULSE Pulsed Field Ablation System
The FARAPULSE PFA System is a new alternative to standard-of-care thermal ablation. During a traditional ablation procedure, a catheter is guided to the interior of the heart and generates extreme temperatures – hot or cold – to destroy targeted areas in the heart associated with abnormal heart rhythms. The FARAPULSE PFA System relies on tissue selective, non-thermal electric fields to ablate heart tissue and avoid damage to surrounding structures.
Positive 12-month data from the pivotal ADVENT clinical trial – the first randomized clinical trial to directly compare the efficacy and safety of the system against standard-of-care ablation – found that therapy with the device was as safe and effective as conventional thermal ablation, with statistically shorter ablation times and a quicker learning curve for physicians. Additional data from more than 17,000 patients demonstrated continued real-world safety of the system, with no reports of permanent phrenic nerve palsy, pulmonary vein stenosis or esophageal injury.
Visit your primary care physician to hear more, or for a referral to the Renown Heart & Vascular Institute. If you would like a primary care physician or practitioner, please visit www.Renown.org or schedule an appointment by calling Renown’s customer service agents available by phone- Mon-Fri: 7 a.m. to 7 p.m., Sat-Sun: 7 a.m. to 6 p.m. at 775-982-5000.
Renown Regional Medical Center has been named #1 Hospital in Nevada by US News & World Report for the past three years as the best hospital for patients with complex, life-threatening, or rare conditions for the last two years and rated highest in NV in eight specialty areas including, Cancer; Cardiology & Heart Surgery; Diabetes & Endocrinology; Gastroenterology & GI Surgery; Nephrology; Neurology & Neurosurgery; Orthopedics; Pulmonology & Lung Surgery.
Renown South Meadows Medical Center in south Reno has earned an “A” Hospital Safety Grade from The Leapfrog Group, the nation’s premier advocate of transparency in health care. This national distinction recognizes Renown Health’s national accomplishments in ensuring safe, high-quality hospital care for patients.
B-roll footage of the cardiac ablation procedure utilizing the FARAPULSE™ Pulsed Field Ablation System is provided by Boston Scientific® and available for media use here.
About Renown Health
Renown Health is the region’s largest, locally governed, not-for-profit integrated health care network serving Nevada, Lake Tahoe, and northeast California. With a diverse workforce of more than 7,400 employees, Renown has fostered a longstanding culture of excellence, determination, and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the locally owned not-for-profit insurance company, Hometown Health.